Circulating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort Terri A. deRoon-Cassini, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara Sander Lee, Karen J. Brasel and Cecilia J. Hillard Translational Psychiatry, 2022, 12, 48, 1-12. Doi : 10.1038/s41398-022-01808-1 The endocannabinoid signaling system (ECSS) regulates fear and anxiety. While ECSS hypoactivity can contribute to symptoms of established post-traumatic stress disorder (PTSD), the role of the ECSS in PTSD development following trauma is unknown. A prospective, longitudinal cohort study of 170 individuals (47% non-Hispanic Caucasian and 70% male) treated at a level 1 trauma [...]
Lire la suiteBibliographie : Cannabinoïdes et PTSD Docteur Christian Sueur, GRECC, mars 2022
Lire la suiteExpérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, GRECC, version 3-5 Dr Christian SUEUR, mars 2022 112 pages Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout en précisant [...]
Lire la suiteDirect comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects Friederike Holze, Laura Ley, Felix Müller, Anna M. Becker, Isabelle Straumann, Patrick Vizeli, Sebastian Silva Kuehne, Marc A. Roder, Urs Duthaler, Karolina E. Kolaczynska, Nimmy Varghese, Anne Eckert and Matthias E. Liechti Neuropsychopharmacology, 2022, 1-8. Doi : 10.1038/s41386-022-01297-2 Growing interest has been seen in using lysergic acid diethylamide (LSD) and psilocybin in psychiatric research and therapy. However, no modern studies have evaluated differences in subjective and autonomic effects of LSD and psilocybin or their similarities and dose equivalence. We used a double blind, randomized, placebo-controlled, [...]
Lire la suiteCannabis is indigenous to Europe and cultivation began during the Copper or Bronze age: a probabilistic synthesis of fossil pollen studies John M. McPartland · Geoffrey W. Guy · William Hegman Vegetation History and Archaeobotany, 2018, 27, 635–648 Doi : 10.1007/s00334-018-0678-7 Abstract Conventional wisdom states Cannabis sativa originated in Asia and its dispersal to Europe depended upon human transport. Various Neolithic or Bronze age groups have been named as pioneer cultivators. These theses were tested by examining fossil pollen studies (FPSs), obtained from the European Pollen Database. Many FPSs report Cannabis or Humulus (C/H) with collective names (e.g. Cannabis/Humulus or Cannabaceae). To dissect these aggregate [...]
Lire la suiteChemical and Morphological Phenotypes in Breeding of Cannabis sativa L. Gianpaolo Grassi and John M. McPartland in S. Chandra et al. (eds.), Cannabis sativa L. - Botany and Biotechnology, Chapter 6, 2017, 137-160. Doi : 10.1007/978-3-319-54564-6_6 Abstract This chapter has two parts. The first part details five characters that contribute to phenotypic diversity in Cannabis. Cannabinoids can be assayed by quantity (dry weight percentage of cannabinoids in harvested material) or by quality (the THC/CBD ratio, or chemotype). Cannabinoid quality is largely genetic, possibly monogenic. We dissect the monogenic inheritance model (two alleles at a single gene locus). Essential oil is composed of volatile, aromatic terpenoids. [...]
Lire la suiteThe Cannabis sativa Versus Cannabis indica Debate : An Interview with Ethan Russo, MD Daniele Piomelli and Ethan B. Russo Cannabis and Cannabinoid Research, 2016, Volume 1.1, 44-46. Doi : 10.1089/can.2015.29003.ebr Dr. Ethan Russo, MD, is a board-certified neurologist, psychopharmacology researcher, and Medical Director of PHYTECS, a biotechnology company researching and developing innovative approaches targeting the human endocannabinoid system. Previously, from 2003 to 2014, he served as Senior Medical Advisor and study physician to GW Pharmaceuticals for three Phase III clinical trials of Sativex for alleviation of cancer pain unresponsive to optimized opioid treatment and studies of Epidiolex for intractable epilepsy. He has held [...]
Lire la suiteThe Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain Ethan B. Russo Frontiers in Plant Science, 2019, Volume 9, Article 1969, 1-8. Doi : 10.3389/fpls.2018.01969 The topic of Cannabis curries controversy in every sphere of influence, whether politics, pharmacology, applied therapeutics or even botanical taxonomy. Debate as to the speciation of Cannabis, or a lack thereof, has swirled for more than 250 years. Because all Cannabis types are eminently capable of cross-breeding to produce fertile progeny, it is unlikely that any clear winner will emerge between the “lumpers” vs. “splitters” in this taxonomical debate. This is compounded [...]
Lire la suiteFibromyalgia and the endocannabinoid system John M. McPartland in Fibromyalgia syndrome : A practitioner’s guide to treatment, chapter 11, 2010, 263-277. Doi : 10.1016/B978-0-443-06936-9.00011-1 CHAPTER CONTENTS Introduction . . . . . . . . . . . . . . . 263 Cannabis and cannabinoid receptors . . 264 Endocannabinoids and their enzymes . 266 Nociception and pain . . . . . . . . . . 266 Around the edges of fibromyalgia . . . . 269 Enhancing the eCB system . . . . . . . 270 Other approaches . . . . . . . . . . . . 272 Conclusions . . . . [...]
Lire la suiteContaminants of Concern in Cannabis : Microbes, Heavy Metals and Pesticides John M. McPartland and Kevin J. McKernan in S. Chandra et al. (eds.), Cannabis sativa L. - Botany and Biotechnology, Chapter 22, 2017, 457-474. Doi : 10.1007/978-3-319-54564-6_22 Abstract Microbiological contaminants pose a potential threat to cannabis consumers. Bacteria and fungi may cause opportunistic infections in immuno-compromized individuals. Even dead organisms may trigger allergies and asthma. Toxins from microbial overloads, such as Shigla toxin and aflatoxins, may pose a problem—unlikely, but possible. The Cannabis plant hosts a robust microbiome; the identification of these organisms is underway. Cannabis bioaccumulates heavy metals in its tissues, so avidly [...]
Lire la suite